NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.00 and traded as high as $0.78. NovaBay Pharmaceuticals shares last traded at $0.71, with a volume of 1,008,684 shares trading hands.
NovaBay Pharmaceuticals Stock Performance
The firm has a market capitalization of $2.97 million, a price-to-earnings ratio of -0.07 and a beta of 2.82.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter. The company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. Analysts expect that NovaBay Pharmaceuticals, Inc. will post -2.54 EPS for the current year.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
Featured Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The Role Economic Reports Play in a Successful Investment Strategy
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Why Invest in High-Yield Dividend Stocks?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.